Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer
1998

Dihydropyrimidine Dehydrogenase and Colorectal Cancer

Sample size: 75 publication Evidence: moderate

Author Information

Author(s): SA Ridge, J Sludden, X Wei, A Sapone, O Brown, S Hardy, P Canney, P Fernandez-Salguero, FJ Gonzalez, J Cassidy, HL McLeod

Primary Institution: University of Aberdeen

Hypothesis

Can DNA mutation analysis identify colorectal cancer patients with low dihydropyrimidine dehydrogenase (DPD) enzyme levels?

Conclusion

The study found that specific mutations in the DPD gene are not significantly associated with low enzyme activity in colorectal cancer patients.

Supporting Evidence

  • The study identified two new mutations in the DPD gene.
  • The splice site mutation was found in 1 out of 72 patients.
  • Mutations at codon 534 were detected in 2 out of 75 patients.
  • The frequency of mutations at codon 543 was found to be 26% in the studied population.

Takeaway

Some people have a gene that makes it hard for their body to handle a cancer medicine called 5-FU, which can make them very sick. This study looked for changes in that gene to help find those people.

Methodology

DNA mutation analysis and measurement of DPD enzyme activity in blood samples from colorectal cancer patients.

Limitations

The study did not measure DPD activity in all individuals with reported mutations, and the sample size may limit generalizability.

Participant Demographics

Patients aged 29-82 years, including those with Duke's stage B, C, and D colorectal cancer.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication